Gene fusions of EWSR1 with members of the CREB family of transcription factors (CREB1, ATF1, and CREM) have recently been described in exceptional intracranial myxoid mesenchymal tumors. Although this is a known gene fusion found in various mesenchymal tumors, EWSR1 fusion with CREM has only been observed in 3 intracranial myxoid tumors. In this paper, we present 1 such tumor with in-depth histopathological description and long-term followup. There is controversy regarding whether these tumors represent a novel entity or simply an intracranial localization of the myxoid variant of angiomatoid fibrous histiocytoma, a rare soft tissue tumor of the extremities. Out of 11 cases mentioned in the literature, the 3 isolated case reports by Dunham et al, Ochalski et al, and Alshareef et al are designated as angiomatoid fibrous histiocytoma, whereas the others are defined as a novel tumoral entity called intracranial myxoid mesenchymal tumor with EWSR1-CREB fusion. We believe the vast morphological and immunohistochemical spectrum of angiomatoid fibrous histiocytoma makes it difficult to dismiss this diagnosis.
INTRODUCTION
Specific gene fusions have been found to play a definitive role in tumorigenesis. The Ewing sarcoma breakpoint region 1 gene (EWSR1), found on chromosome 22q12, has a propensity to fuse with cAMP response element binding (CREB) family genes such as CREB1, CREM, and ATF1 (1). Although the mechanism underlying this fusion's tumorigenic potential has yet to be fully understood, it is believed to play a role in DNA damage response and cell division (2) . It has been described in histopathologically diverse mesenchymal tumors such as angiomatoid fibrous histiocytoma (AFH), primary pulmonary myxoid sarcoma, clear cell sarcoma, as well as myoepithelial tumors, hyalinizing clear cell carcinomas of salivary glands, and recently in a melanoma (1, 3) . It has thus become apparent that certain gene fusions are not sufficient to confirm a diagnosis since these EWSR1-CREB fused lesions give way to a large spectrum of tumors with variable morphology and immunoprofile.
Classically, EWSR1-CREB is known to be the predominant gene fusion in AFH (4) . AFH is a rare soft tissue tumor of low to medium malignant potential that usually presents in children and young adults, found in the subcutis or deep dermis of the extremities (5) . Histopathologically, the most typical diagnostic features are a thick fibrous pseudocapsule, nodular growth of spindled, ovoid, or pleomorphic cells arranged in a syncytial pattern, pseudoangiomatoid spaces, and lymphocyte cuffing (6, 7) . However, it should be noted that AFH exhibits a very wide morphological spectrum, including a myxoid variant (8) . AFH confirmed by EWSR1 rearrangements within the central nervous system (CNS) is rare and has been described in 6 isolated cases in young adults and children (6, (8) (9) (10) (Table) . On the other hand, Kao et al (11) and Sciot et al (12) focused on 5 intracranial myxoid mesenchymal neoplasms carrying this fusion and suggest a novel tumoral entity called primary myxoid mesenchymal tumor with intracranial location, with an EWSR1-CREB fusion yet lacking certain morphological characteristics of myxoid AFH. Our study focuses on an intracranial, myxoid, mesenchymal tumor harboring a fusion of EWSR1 with CREM, with long-term follow-up information and a literature review.
Case Presentation
In 2007, a 19-year-old man presented with epileptic partial seizures with increasing frequency (1 in 2006, and 6 in the 3-month period prior to diagnosis). No systemic symptoms such as anemia, fever, or weight loss were noted. Familial medical history was noncontributory. Brain imaging studies showed a large lesion in the right tentorium cerebelli. He underwent surgery to remove an extra-axial temporo-occipital lesion and 2 well-delineated nodules measuring 6 and 2 cm in diameter, respectively, were removed. Postoperative magnetic resonance imaging (MRI) confirmed a complete tumor resection. He was treated with 6 cycles of API/AI type chemotherapy and external conformational radiotherapy with modulation intensity of the post-operative cavity (61.2 Gy, by 34 fractions of 1.8 Gy).
Ten years later, this patient presented with subcutaneous swelling behind the right ear. Preoperative MRI demonstrated a large, heterogeneous, and contrast-enhancing lesion with both solid and cystic components infiltrating the dura matter in the tentorium and temporal lobe (Fig. 1A) . The solid counterpart measured $6 cm in diameter and the cystic counterpart 5 cm, seen after gadolinium injection. Perilesional vasogenic edema was observed on Fluid Attenuated Inversion Recovery sequence (Fig. 1B) . Extension into infra-tentorial regionsnotably the cerebellum-and into the subcutaneous region were also observed, unlike in the primary tumor (Fig. 1C) . He underwent surgery to remove the intracerebral, dural, bone and subcutaneous components of the tumor, a duraplasty and a cranioplasty were performed.
MATERIALS AND METHODS
Both primitive and recurrent tumors were stained with hematoxylin, eosin, and saffron for histological examination. Total RNAs were isolated from crushed frozen tumors using a Trizol reagent kit (Life Technologies, Alfortville, France). Library construction was performed following the TruSeq Stranded mRNA LS protocol (Ref RS-122-2101 ILLUMINA). Paired-end RNA sequencing was processed on the NextSeq 500 (150 nt paired-end) Illumina sequencing machine. Bioinformatics analyses were carried out for fusion gene discovery, sequencing reads were injected into both the TopHat, deFuse tools [12] and the FusionMap tool [13] with hg19 genome as reference. Only fusion transcripts supported 
to cerebellum/intra and extra-axial
CPA, cerebello-pontine angle; DOD, dead of disease; EWSR1*, EWSR1 with unknown fusion partner; F, female; M, male; N/A, not available.
by both tools with at least 2 split reads (and 3 spanning pairs for deFuse) were considered. Break-apart fluorescent in situ hybridization (FISH) of the EWSR1 locus was performed by using the Dual Color EWSR1 Break Apart probe (Zytovision, Clinisciences, Bremerhaven, Germany). Signals were counted in 100 tumor nuclei by using a DM600 imaging fluorescence microscope (Leica Biosystems, Richmond, IL) fitted with appropriate filters, a CCD camera, and digital imaging software from Leica (Cytovision, v7.4). FISH for gene rearrangement was considered positive if at least 20% of analyzed cells showed a split of at least 1 set of red and green signals or an isolated (red or green) signal.
RESULTS
Upon microscopic evaluation, the primary and recurrent tumors were almost identical. They presented as heterogeneous, nodular lesions that were well delineated and did not come into contact with normal brain parenchyma ( Fig. 2A) . Both focally invaded the dura matter. The nodules were made up of areas of higher cell density arranged in a trabecular pattern, areas of predominantly spindle cells, and areas of lower cell density and abundant collagen (Fig. 2B) . Cell morphology ranged from round to spindle shaped to pleomorphic. The tumor cell cytoplasm was clear and mildly eosinophilic. Neoplastic nuclei were irregular, had prominent nucleoli, and occasionally presented with intranuclear inclusions (Fig. 2C) . Only rare lymphocytes were observed. No rhabdoid cells were seen. We noticed small foci of necrosis and some vascular proliferation, but no pseudoangiomatoid spaces. The stroma was mainly collagenous, with marked myxoid areas and very few inflammatory infiltrates (Fig. 2D) . The mitotic count was 5 mitoses for 10 high-power fields (HPFs) (Â400) with an estimated Ki67 index of 10% in the primary tumor.
The recurrent tumor, although very similar, had a more widespread myxoid component. The nodules sometimes centered on necrotic zones and a more prominent, rigid vasculature was observed (Fig. 2B, E) . We noticed areas of dedifferentiation marked by an increase in cellular density and a high nuclear to cytoplasmic ratio, but without an increase in mitotic rate or necrosis (Fig. 2F ) No rhabdoid changes were seen. The mitotic rate also increased heterogeneously from area to area, reaching up to 54 mitoses for 10 HPFs (Â400) and an estimated Ki67 index of 40% (Fig. 2C) . Samples taken from the infiltrative subcutaneous zone and within the bone are representative of widespread tumoral infiltration.
Immunohistochemical analysis of the primitive revealed tumor cells reacting focally with CD99, vimentin, and S100 protein (Fig. 2G) . A few cells were positive for EMA. Neoplastic cells were negative for desmin and CD34, as well as smooth muscle actin. Immunohistochemistry for the recurrent tumor did not show a loss of INI1 or BRG1. The lesion remains clearly delineated from the adjacent parenchyma and CD56 negative. Tumor cells, dedifferentiated or not, showed cytoplasmic positivity for EMA, but were negative for desmin (Fig. 2H) . Cytokeratin AE1/AE3, HMB45, SSTR2A, CD99, CD34, GFAP and chromogranin A were negative in tumor cells.
The biomolecular study revealed an EWSR1-CREM fusion encompassing the fusion between EWSR1 exon7 (NM_005243) and CREM exon13 (NM_181571). FISH analysis allowed us to further confirm the presence of a complex EWSR1 rearrangement. An unbalanced rearrangement with loss of the 3 0 locus during the translocation was observed in 40% of tumor cells (Fig. 2I) . Postoperatively, the MRI confirmed a complete resection and the patient underwent a focal re-irradiation by Volumetric Modulated Arc Therapy (VMAT) of 50 Gy (20 fractions of 2.5 Gy).
DISCUSSION
In the past, pathologists had a tendency to name tumors differently when they arose intracranially as opposed to the rest of the body, when they are in fact the same nosological entity. Such is the case for atypical teratoid/rhabdoid tumors found in the CNS, named rhabdoid tumors when they arise extra cranially, as well as the distinction between solitary fibrous tumors and hemangiopericytoma done in CNS tumors but not in the rest of the body (13) .
The present tumor shows similar features to myxoid AFH: a young age at diagnosis, and a well-delineated, lobulated tumor with marked myxoid regions and an EWSR1-CREB fusion (14) . Expression of EMA and CD99, typically expressed in AFH, was positive in this case. However, up to 50% of AFHs are desmin positive, whereas ours was not. This tumor was also lacking distinctive lymphocyte cuffing and the fibrous pseudocapsule typically found in AFH. While it had significant vascularization, it did not present with the characteristic blood-filled spaces of AFH. However, in an overview on the current status of AFH pathology and genetics, Thway et al assert that only $80% of AFHs are surrounded by a lymphoplasmacytic cuff (7) . The series by Schaefer and Fletcher and Shi et al, respectively, describe 4/21 and 8/21 myxoid variants of AFH that are lacking pseudoangiomatoid spaces (14, 15) . Mitoses are usually rare in AFH, however, atypical cases with high mitotic rate, cellular pleomorphism, and nuclear atypia have been described (7, 15) . Thus, these studies provide evidence that AFH is a neoplasm that exhibits a wide morphological spectrum. Furthermore, rare cases of intracranial AFH have been described in the literature (Table) (6, 9, 10) . These tumors presented with the morphological hallmarks of AFH and a rearrangement of the EWSR1 gene, although the fusion partner was not always specified. Myxoid features as seen in our tumor were not specifically described in these AFHs.
It is also important to distinguish this tumor from other EWSR1-CREB fused mesenchymal neoplasms. Thus, the location of the tumor, as well as immunohistochemical markers are of diagnostic importance. Primary pulmonary myxoid sarcoma is primarily found in endobronchial lesions and in older patients. It has a characteristic reticular pattern and is usually vimentin-positive and desmin-negative but nonetheless shares significant morphological and immunohistochemical overlap with AFH, which needs to be further characterized (1) . Myoepithelial tumors express GFAP, cytokeratin, and S100, and the known intracranial cases did not harbor an EWSR1 rearrangement (1). Our tumor was negative for HMB45 and MelanA, which exclude the diagnoses of clear cell sarcoma and melanoma.
The reports by Kao et al, Bale et al, and Sciot et al mentioned intracranial, myxoid, mesenchymal tumors characterized by EWSR1-CREB fusions, including 2 with EWSR1-CREM (8, 11, 12) . CREM is the least well-defined of the CREB family transcription factors, and its significance still needs to be evaluated (8) . These 3 studies show many similitudes with our case: An intracranial location, presenting in adolescents or young adults, a well-delineated myxoid tumor with a rearranged EWSR1 gene. Whereas Kao et al and Bale et al observed tumors that often presented with amianthoid fibers (thick collagen fibers) with a starburst appearance and ours did not, it should be noted that all tumors including ours had an important collagen counterpart that has not yet been described in myxoid or classic intracranial AFH. These correlations lead us to believe that these tumors belong to a single tumoral entity. It should be noted that in our case, aggressive histological features were observed in the recurrent tumor (dedifferentiation, necrosis, high mitotic index). Kao et al went so far as to suggest a novel entity defined by an intracranial EWSR1-CREB fusion, yet lacking the vascular and lymphocytic aspects of myxoid AFH. The immunoprofile of our case is compatible both with the aforementioned studies and AFH. While in each of the 3 articles the patients presented with tumors lacking certain of the diagnostic hallmarks of AFH, its intrinsic morphological variability made it difficult to exclude this diagnosis completely. The prognosis for AFH is generally favorable, although local recurrence has been observed in 15% of cases, with <5% leading to metastatic disease (7). The case study by Sciot et al provides long-term follow-up information about a tumor that recurred twice in the frontal lobe over the course of 7 years (12). It was treated by surgical resection followed by radiotherapy, and the patient is currently free of disease. The other studies give scarce information pertaining to follow up in intracranial cases, Kao et al briefly mentioned an uneventful 17 months after resection in 2 cases. Our case is defined by local recurrence of an almost identical tumor at a 10-year disease free interval after initial resection and radiotherapy.
In conclusion, we report a case of an intracranial, myxoid, mesenchymal tumor harboring an EWSR1-CREM fusion. Due to the variability in AFH's histopathological and immunological markers, it is difficult to deny the possibility that these tumors might all belong to the same nosological entity.
